Weak Angiomax sales hit Medicines Company Q1 expectations
This article was originally published in Scrip
Executive Summary
The Medicines Company is expecting weak first quarter total net revenues thanks to lower sales of Angiomax (bivalirudin), says the firm. It now expects net revenues for the anticoagulant of between $97m and $105m, down from $155.7m in the first quarter of 2014. Total net revenues are likely to reach between $125m and $130m, which marks a 26-29% drop on last year's first quarter revenues of $177.2m. The firm blames the decline on uncertainty over Angiomax's patent exclusivity in the US past June 2015 when a final decision on Hospira's patent challenge is expected. Analysts at Jefferies have reduced their price target for the firm from $27 to $26. Final first quarter results will be released in May.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.